TABLE 3.
Results of intention-to-treat analysis by pathogenic variant type.
| Nonsynonymous CG (N = 16) | Nonsynonymous IG (N = 38) | p* | LOF CG (N = 157) | LOF IG (N = 155) | p* | p** | |
|---|---|---|---|---|---|---|---|
| Δ of differences | Δ of differences | Δ of differences | Δ of differences | ||||
| Weight (kg) | −0.7 ± 3.3 | −1.4 ± 3.7 | 0.60 | −0.7 ± 2.4 | −1.5 ± 2.7 | <0.01 | 0.62 |
| BMI (kg/m2) | −0.3 ± 1.3 | −0.6 ± 1.4 | 0.59 | −0.3 ± 0.9 | −0.6 ± 1.1 | <0.01 | 0.67 |
| Waist circumference (cm) | −0.3 ± 3.1 | −2.0 ± 5.8 | 0.51 | −0.8 ± 4.7 | −2.1 ± 5.2 | 0.01 | 0.54 |
| Hip circumference (cm) | −0.4 ± 2.6 | −1.2 ± 3.9 | 0.50 | −0.5 ± 4.7 | −1.8 ± 4.3 | <0.01 | 0.36 |
| Systolic pressure (mmHg) | +3.4 ± 11.8 | +0.3 ± 16.4 | 0.94 | −4.0 ± 13.4 | −4.1 ± 14.9 | 0.62 | <0.01 |
| Diastolic pressure (mmHg) | +0.2 ± 6.6 | −1.4 ± 10.9 | 0.78 | −2.6 ± 9.8 | −2.7 ± 11.1 | 0.77 | 0.46 |
| Glycemia (mg/dl) | −10.8 ± 30.5 | −8.2 ± 21.8 | 0.98 | −8.8 ± 22.8 | −7.3 ± 19.0 | 0.62 | 0.64 |
| Total cholesterol (mg/dl) | −9.0 ± 29.0 | −8.0 ± 21.6 | 0.69 | −4.6 ± 28.3 | −11.7 ± 25.4 | 0.04 | 0.84 |
| HDL cholesterol (mg/dl) | +0.3 ± 11.7 | +2.8 ± 12.1 | 0.65 | +0.1 ± 13.9 | +2.0 ± 12.3 | 0.09 | 0.59 |
| LDL cholesterol (mg/dl) | −10.8 ± 24.4 | −2.0 ± 22.1 | 0.22 | −6.0 ± 26.1 | −6.9 ± 24.5 | 0.90 | 0.71 |
| Triglycerides (mg/dl) | +5.5 ± 44.3 | −18.0 ± 100.5 | 0.41 | +5.8 ± 43.6 | −6.0 ± 49.8 | 0.02 | 0.18 |
| IGF-I (ng/ml) | +0.2 ± 39.5 | −10.5 ± 38.5 | 0.42 | −0.9 ± 43.2 | −9.3 ± 43.1 | 0.18 | 0.74 |
| Insulin (µIU/ml) | −2.8 ± 17.8 | −3.3 ± 13.2 | 0.43 | −4.9 ± 18.5 | −8.8 ± 16.6 | 0.04 | <0.01 |
| CRP (mg/L) | −0.8 ± 1.1 | +0.4 ± 2.5 | 0.29 | −0.3 ± 2.5 | −0.3 ± 1.7 | 0.96 | 0.20 |
*
p of comparison between the randomization groups: ANOVA, controlling for age (tertiles), study center, BMI at baseline (tertiles), and the baseline value of the variable under study.
**
p of comparison between the pathogenic variants: ANOVA, including the pathogenic variant type into the model.